JS105 + fulvestrant

JS105 + fulvestrant is an investigational combination therapy being evaluated for advanced solid tumors, especially recurrent/metastatic triple-negative breast cancer and advanced gynecologic tumors. JS105 is a novel drug candidate (mechanism not fully disclosed in public sources; likely an anti-tumor agent), combined with fulvestrant, a selective estrogen receptor degrader (SERD) that binds, blocks, and promotes degradation of the estrogen receptor, inhibiting estrogen signaling in hormone receptor-positive cancers. The combination aims to improve outcomes in settings with endocrine resistance or limited response to hormone therapies. As of the latest records, JS105 + fulvestrant is under investigation in phase Ib/II clinical trials for solid tumors, particularly breast and gynecologic cancers[3][4][5].